샘플 요청 목록

 카트 문의
시장보고서
상품코드
1774879

세계의 GLP-1 수용체 작용제 시장

GLP-1 Receptor Agonist
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 483 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계 GLP-1 수용체 작용제 시장은 2030년까지 1,374억 달러에 도달

2024년에 519억 달러로 추정되는 GLP-1 수용체 작용제 세계 시장은 2024-2030년간 CAGR 17.6%로 성장하여 2030년에는 1,374억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 Ozempic는 CAGR19.2%를 나타내고, 분석 기간 종료시에는 454억 달러에 이를 것으로 예측됩니다. Trulicity 부문의 성장률은 분석 기간중 CAGR 18.8%로 추정됩니다.

미국 시장은 약 141억 달러, 중국은 CAGR 23.4%로 성장 예측

미국의 GLP-1 수용체 작용제 시장은 2024년에 141억 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2030년까지 308억 달러 규모에 이를 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 23.4%로 추정됩니다. 기타 주목해야 할 지역별 시장으로서는 일본과 캐나다가 있으며, 각각 분석 기간 중에 12.9%와 16.0%의 연평균 복합 성장률(CAGR)을 나타낼 전망입니다. 유럽에서는 독일이 CAGR 약 14.1%로 성장할 전망입니다.

세계의 GLP-1 수용체 작용제 시장 - 주요 동향과 촉진요인 정리

GLP-1 수용체 작용제가 당뇨병 및 비만 치료에 변화를 가져올 수 있는 이유는?

글루카곤 유사 펩타이드-1(GLP-1) 수용체 작용제는 2형 당뇨병 및 비만증의 획기적인 치료제로 등장하여 기존 치료제에 비해 우수한 혈당 조절 및 체중 감소 효과를 가져왔습니다. 이들 주사제 및 경구용 약물은 혈당을 조절하고 인슐린 분비를 촉진하며 위 배출을 지연시키는 호르몬인 GLP-1의 작용을 모방하여 당 대사를 개선하고 식욕을 억제하는 효과를 가져옵니다. 전 세계적으로 당뇨병과 비만 유병률이 증가함에 따라 GLP-1 수용체 작용제는 현대 대사질환 관리의 핵심이 되고 있습니다.

이 시장에서는 주 1회 투여 제제, 병용요법, 경구용 GLP-1 수용체 작용제의 도입 등 환자의 순응도와 치료 효과를 향상시키는 큰 진전이 이루어지고 있습니다. 제약사들은 GLP-1 약물의 치료 용도 확대에 많은 투자를 하고 있으며, 심혈관 질환, 신경 퇴행성 질환, 비알코올성 지방간 질환(NAFLD)에서의 가능성을 모색하고 있습니다. 의료진들이 효과적이고 장기적인 치료 옵션을 우선시하는 경향이 높아지면서 GLP-1 수용체 작용제에 대한 수요는 지속적으로 증가하고 있습니다.

GLP-1 수용체 작용제 수요를 주도하는 환자군 및 치료 영역은?

GLP-1 수용체 작용제의 주요 시장은 2형 당뇨병 환자이며, 저혈당 위험을 최소화하면서 우수한 혈당 조절을 제공하며, GLP-1 수용체 작용제는 체중 감소를 촉진하여 비만 치료제로도 주목받고 있으며, 규제 당국의 승인을 받아 당뇨병 치료 외의 용도로도 사용되고 있습니다. 용도로도 사용되고 있습니다. 임상시험에서 비만 환자에서 유의미한 체중 감소가 입증되어 GLP-1 수용체 작용제는 체중 조절을 위한 주요 약리학적 솔루션으로 자리매김하고 있습니다.

GLP-1 수용체 작용제는 당뇨병과 비만 외에도 심혈관 질환 예방에 대한 GLP-1 수용체 작용제의 역할에 대한 연구가 진행되고 있으며, 고위험군 환자에서 주요 심혈관 사건(MACE)을 감소시키는 것으로 나타났습니다. 또한, 알츠하이머병과 같은 신경퇴행성 질환의 치료에서도 GLP-1 수용체 작용제가 신경보호 작용을 나타낼 가능성이 검토되고 있으며, GLP-1 수용체 작용제가 다기능 치료제로 인식되고 있어 다양한 치료 영역에서 시장 가능성이 확대되고 있습니다.

GLP-1 의약품 개발의 최신 기술 혁신은 무엇인가?

제약업계는 유효성, 편의성, 환자 순응도 향상에 중점을 두고 의약품 개발에 큰 진전을 이루었습니다. 가장 주목할 만한 혁신 중 하나는 경구용 GLP-1 수용체 작용제의 도입으로, 주사를 맞을 필요가 없어져 더 많은 환자들이 치료에 접근할 수 있게 되었습니다. 또한, 주 1회 투여 및 2제 병용요법과 같은 서방형 제제를 통해 치료 순응도가 향상되고, 대사 개선 효과가 장기간 지속될 수 있게 되었습니다.

또 다른 주요 발전은 이중 또는 삼중 수용체 활성을 가진 GLP-1 수용체 작용제 개발로, 여러 대사 경로를 표적으로 삼아 혈당 조절과 체중 감소를 강화하는 것. AI 기반 신약 개발은 약동학 및 안전성 프로파일이 개선된 새로운 GLP-1 유사체 발굴을 가속화할 것으로 보입니다. 하고 있습니다. 또한, 커넥티드 인슐린 펜과 실시간 혈당 모니터링과 같은 디지털 헬스 솔루션의 통합은 개인화된 치료 권장 사항을 제공함으로써 GLP-1 치료의 효과를 높이고 있습니다. 이러한 기술 혁신은 대사성 질환 관리의 미래를 형성하고 있으며, GLP-1 수용체 작용제를 보다 효과적이고 쉽게 사용할 수 있도록 돕고 있습니다.

GLP-1 수용체 작용제 시장의 성장을 가속하는 요인은 무엇인가?

GLP-1 수용체 작용제 시장의 성장은 당뇨병 및 비만 유병률 증가, 치료 목적의 확대, 약물 제형의 발전 등 여러 요인에 기인하며, GLP-1 수용체 작용제가 효과적인 체중 관리 솔루션으로 인식되면서 당뇨병 환자뿐만 아니라 비당뇨병 환자들에게도 폭넓게 채택되고 있습니다. 널리 채택되고 있습니다. 또한, 경구용 약물 및 이중 길항제와 같은 새로운 제제에 대한 규제 당국의 승인은 시장 성장을 가속하고 있습니다.

제약업계의 대사성 질환 연구에 대한 투자와 차세대 GLP-1 수용체 작용제 시장 개척이 시장 확대에 더욱 박차를 가하고 있습니다. 또한, 비만 치료를 지원하는 보험 적용 및 상환 정책도 GLP-1 치료제에 대한 환자 접근성 확대에 일조하고 있습니다. 또한, 디지털 헬스 솔루션과 AI 기반 정밀의료의 통합은 치료 결과를 최적화하고, GLP-1 수용체 작용제는 대사성 질환 관리에 있어 선호되는 선택이 되고 있습니다. 혁신적이고 효과적인 치료법에 대한 수요가 지속적으로 증가함에 따라 GLP-1 수용체 작용제 시장은 강력하고 지속적인 성장이 예상됩니다.

부문

제품 유형(Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound, 기타 제품), 투여 경로(비경구, 경구), 유통 채널(병원 약국 유통 채널, 소매 약국 유통 채널, 온라인 약국 유통 채널), 용도(2형 당뇨병 용도, 비만 용도)

조사 대상 기업 예

  • Amgen Inc.
  • Ascendis Pharma A/S
  • AstraZeneca
  • BioAtla, Inc.
  • Boehringer Ingelheim International GmbH
  • Eli Lilly and Company
  • Genentech, Inc.
  • Hansoh Pharmaceutical Group
  • ImCyse SA
  • Innovent Biologics, Inc.
  • Lexicon Pharmaceuticals
  • Metsera, Inc.
  • Novo Nordisk A/S
  • Orgenesis Inc.
  • PegBio Co., Ltd.
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi
  • The United Laboratories International Holdings Limited
  • Viking Therapeutics, Inc.

AI 통합

Global Industry Analysts는 유효한 전문가 컨텐츠와 AI툴에 의해서, 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 일반적인 LLM나 업계별 SLM 쿼리에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 대량 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수익원가(COGS) 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

LSH 25.07.31

Global GLP-1 Receptor Agonist Market to Reach US$137.4 Billion by 2030

The global market for GLP-1 Receptor Agonist estimated at US$51.9 Billion in the year 2024, is expected to reach US$137.4 Billion by 2030, growing at a CAGR of 17.6% over the analysis period 2024-2030. Ozempic, one of the segments analyzed in the report, is expected to record a 19.2% CAGR and reach US$45.4 Billion by the end of the analysis period. Growth in the Trulicity segment is estimated at 18.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$14.1 Billion While China is Forecast to Grow at 23.4% CAGR

The GLP-1 Receptor Agonist market in the U.S. is estimated at US$14.1 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$30.8 Billion by the year 2030 trailing a CAGR of 23.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 12.9% and 16.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 14.1% CAGR.

Global GLP-1 Receptor Agonist Market - Key Trends & Drivers Summarized

Why Are GLP-1 Receptor Agonists Transforming Diabetes and Obesity Treatment?

Glucagon-like peptide-1 (GLP-1) receptor agonists have emerged as a breakthrough treatment for type 2 diabetes and obesity, offering superior glycemic control and weight loss benefits compared to traditional therapies. These injectable and oral medications mimic the action of GLP-1, a hormone that regulates blood sugar levels, promotes insulin secretion, and slows gastric emptying, leading to improved glucose metabolism and appetite suppression. With the rising prevalence of diabetes and obesity worldwide, GLP-1 receptor agonists have become a cornerstone of modern metabolic disease management.

The market has seen significant advancements, including the introduction of once-weekly formulations, combination therapies, and oral GLP-1 receptor agonists, which have improved patient compliance and treatment efficacy. Pharmaceutical companies are investing heavily in expanding the therapeutic applications of GLP-1 drugs, exploring their potential in cardiovascular disease, neurodegenerative disorders, and non-alcoholic fatty liver disease (NAFLD). As healthcare providers increasingly prioritize effective and long-lasting treatment options, the demand for GLP-1 receptor agonists continues to grow.

Which Patient Populations and Therapeutic Areas Are Driving Demand for GLP-1 Receptor Agonists?

The primary market for GLP-1 receptor agonists is patients with type 2 diabetes, where these drugs offer superior blood sugar control while minimizing the risk of hypoglycemia. Given their ability to promote weight loss, these medications are also gaining traction in the treatment of obesity, with regulatory approvals expanding their use beyond diabetes management. Clinical trials have demonstrated significant weight reduction in obese patients, positioning GLP-1 receptor agonists as a leading pharmacological solution for weight management.

Beyond diabetes and obesity, research is exploring the role of GLP-1 receptor agonists in cardiovascular disease prevention, as these drugs have shown a reduction in major adverse cardiovascular events (MACE) in high-risk patients. Additionally, ongoing studies are investigating their potential in treating neurodegenerative disorders such as Alzheimer’s disease, where GLP-1 analogs may exhibit neuroprotective effects. The growing recognition of GLP-1 receptor agonists as a multi-functional therapy is expanding their market potential across diverse therapeutic areas.

What Are the Latest Technological Innovations in GLP-1 Drug Development?

The pharmaceutical industry has made significant strides in GLP-1 receptor agonist drug development, focusing on improving efficacy, convenience, and patient adherence. One of the most notable innovations is the introduction of oral GLP-1 receptor agonists, eliminating the need for injections and making treatment more accessible to a broader patient population. Additionally, extended-release formulations, such as once-weekly and dual-agonist therapies, have enhanced treatment adherence and provided prolonged metabolic benefits.

Another key advancement is the development of GLP-1 receptor agonists with dual or triple receptor activity, targeting multiple metabolic pathways to enhance glucose control and weight reduction. AI-driven drug discovery is also accelerating the identification of novel GLP-1 analogs with improved pharmacokinetics and safety profiles. Furthermore, the integration of digital health solutions, such as connected insulin pens and real-time glucose monitoring, is enhancing the effectiveness of GLP-1 therapy by providing personalized treatment recommendations. These innovations are shaping the future of metabolic disease management, making GLP-1 receptor agonists more effective and accessible.

What Factors Are Fueling the Growth of the GLP-1 Receptor Agonist Market?

The growth in the GLP-1 receptor agonist market is driven by several factors, including the rising global prevalence of diabetes and obesity, expanding therapeutic applications, and advancements in drug formulations. The increasing awareness of GLP-1 receptor agonists as an effective weight management solution has contributed to broader adoption beyond diabetic populations. Additionally, regulatory approvals for new formulations, including oral and dual-agonist therapies, have strengthened market growth.

The pharmaceutical industry’s investment in metabolic disease research and the development of next-generation GLP-1 receptor agonists have further fueled market expansion. Insurance coverage and reimbursement policies supporting obesity treatment have also played a role in increasing patient access to GLP-1 therapies. Furthermore, the integration of digital health solutions and AI-driven precision medicine is optimizing treatment outcomes, making GLP-1 receptor agonists a preferred choice for managing metabolic disorders. As demand for innovative and effective treatments continues to rise, the GLP-1 receptor agonist market is expected to experience strong and sustained growth.

SCOPE OF STUDY:

The report analyzes the GLP-1 Receptor Agonist market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound, Other Products); Route of Administration (Parenteral, Oral); Distribution Channel (Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel); Application (Type 2 Diabetes Mellitus Application, Obesity Application)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • Amgen Inc.
  • Ascendis Pharma A/S
  • AstraZeneca
  • BioAtla, Inc.
  • Boehringer Ingelheim International GmbH
  • Eli Lilly and Company
  • Genentech, Inc.
  • Hansoh Pharmaceutical Group
  • ImCyse SA
  • Innovent Biologics, Inc.
  • Lexicon Pharmaceuticals
  • Metsera, Inc.
  • Novo Nordisk A/S
  • Orgenesis Inc.
  • PegBio Co., Ltd.
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi
  • The United Laboratories International Holdings Limited
  • Viking Therapeutics, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • GLP-1 Receptor Agonist - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Prevalence of Type 2 Diabetes and Obesity Drives Demand for GLP-1 Receptor Agonist Therapies
    • Strong Clinical Evidence Supporting Weight Loss Benefits Strengthens Market Expansion Beyond Diabetes
    • FDA Approvals for New Indications and Weekly Dosing Regimens Accelerate Patient Adoption
    • Growing Interest in Cardiovascular Risk Reduction Enhances Therapeutic Scope of GLP-1 Drugs
    • Pharma Investment in Oral and Long-Acting Formulations Boosts Convenience and Compliance
    • Expansion of Reimbursement Programs and Insurance Coverage Supports Market Accessibility
    • High Patient Awareness and Direct-to-Consumer Marketing Fuel Demand for Branded GLP-1 Therapies
    • Rising Use in Medically Supervised Weight Management Programs Drives Volume Growth
    • Ongoing Innovation in Dual and Triple Agonists Enhances Competitive Differentiation
    • M&A Activity and Strategic Alliances Among Biopharma Companies Accelerate Pipeline Expansion
    • Shift Toward Personalized Medicine and Biomarker-Based Therapies Opens Niche Treatment Segments
    • Clinical Trials Exploring GLP-1 Role in NAFLD and NASH Unlock Future Market Opportunities
    • Epidemiological Transition in Developing Markets Expands Growth Potential in Asia and Latin America
    • Growing Telehealth and Digital Prescription Platforms Boost Accessibility to GLP-1 Therapies
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World GLP-1 Receptor Agonist Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for GLP-1 Receptor Agonist by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for GLP-1 Receptor Agonist by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Ozempic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Ozempic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Ozempic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Trulicity by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Trulicity by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Trulicity by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Mounjaro by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Mounjaro by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Mounjaro by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Wegovy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Wegovy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Wegovy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Rybelsus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Rybelsus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Rybelsus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Saxenda by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Saxenda by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Saxenda by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Victoza by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Victoza by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Victoza by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Zepbound by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Zepbound by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Zepbound by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Other Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Parenteral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Hospital Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Hospital Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: World 15-Year Perspective for Hospital Pharmacies Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Retail Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Retail Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: World 15-Year Perspective for Retail Pharmacies Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 44: World Recent Past, Current & Future Analysis for Online Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 45: World Historic Review for Online Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: World 15-Year Perspective for Online Pharmacies Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 47: World Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 48: World Historic Review for Type 2 Diabetes Mellitus Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: World 15-Year Perspective for Type 2 Diabetes Mellitus Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 50: World Recent Past, Current & Future Analysis for Obesity Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: World Historic Review for Obesity Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: World 15-Year Perspective for Obesity Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • GLP-1 Receptor Agonist Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 53: USA Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: USA Historic Review for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: USA 15-Year Perspective for GLP-1 Receptor Agonist by Product - Percentage Breakdown of Value Sales for Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products for the Years 2015, 2025 & 2030
    • TABLE 56: USA Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: USA Historic Review for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: USA 15-Year Perspective for GLP-1 Receptor Agonist by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 59: USA Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: USA Historic Review for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: USA 15-Year Perspective for GLP-1 Receptor Agonist by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
    • TABLE 62: USA Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: USA Historic Review for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: USA 15-Year Perspective for GLP-1 Receptor Agonist by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application and Obesity Application for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 65: Canada Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Canada Historic Review for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Canada 15-Year Perspective for GLP-1 Receptor Agonist by Product - Percentage Breakdown of Value Sales for Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products for the Years 2015, 2025 & 2030
    • TABLE 68: Canada Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Canada Historic Review for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Canada 15-Year Perspective for GLP-1 Receptor Agonist by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 71: Canada Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Canada Historic Review for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Canada 15-Year Perspective for GLP-1 Receptor Agonist by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
    • TABLE 74: Canada Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Canada Historic Review for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Canada 15-Year Perspective for GLP-1 Receptor Agonist by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application and Obesity Application for the Years 2015, 2025 & 2030
  • JAPAN
    • GLP-1 Receptor Agonist Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 77: Japan Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Japan Historic Review for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Japan 15-Year Perspective for GLP-1 Receptor Agonist by Product - Percentage Breakdown of Value Sales for Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products for the Years 2015, 2025 & 2030
    • TABLE 80: Japan Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Japan Historic Review for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Japan 15-Year Perspective for GLP-1 Receptor Agonist by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 83: Japan Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Japan Historic Review for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Japan 15-Year Perspective for GLP-1 Receptor Agonist by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
    • TABLE 86: Japan Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Japan Historic Review for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Japan 15-Year Perspective for GLP-1 Receptor Agonist by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application and Obesity Application for the Years 2015, 2025 & 2030
  • CHINA
    • GLP-1 Receptor Agonist Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 89: China Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: China Historic Review for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: China 15-Year Perspective for GLP-1 Receptor Agonist by Product - Percentage Breakdown of Value Sales for Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products for the Years 2015, 2025 & 2030
    • TABLE 92: China Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: China Historic Review for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: China 15-Year Perspective for GLP-1 Receptor Agonist by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 95: China Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: China Historic Review for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: China 15-Year Perspective for GLP-1 Receptor Agonist by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
    • TABLE 98: China Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: China Historic Review for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: China 15-Year Perspective for GLP-1 Receptor Agonist by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application and Obesity Application for the Years 2015, 2025 & 2030
  • EUROPE
    • GLP-1 Receptor Agonist Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 101: Europe Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 102: Europe Historic Review for GLP-1 Receptor Agonist by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Europe 15-Year Perspective for GLP-1 Receptor Agonist by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 104: Europe Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Europe Historic Review for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Europe 15-Year Perspective for GLP-1 Receptor Agonist by Product - Percentage Breakdown of Value Sales for Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products for the Years 2015, 2025 & 2030
    • TABLE 107: Europe Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Europe Historic Review for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Europe 15-Year Perspective for GLP-1 Receptor Agonist by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 110: Europe Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Europe Historic Review for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Europe 15-Year Perspective for GLP-1 Receptor Agonist by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
    • TABLE 113: Europe Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Europe Historic Review for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Europe 15-Year Perspective for GLP-1 Receptor Agonist by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application and Obesity Application for the Years 2015, 2025 & 2030
  • FRANCE
    • GLP-1 Receptor Agonist Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 116: France Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: France Historic Review for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: France 15-Year Perspective for GLP-1 Receptor Agonist by Product - Percentage Breakdown of Value Sales for Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products for the Years 2015, 2025 & 2030
    • TABLE 119: France Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: France Historic Review for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: France 15-Year Perspective for GLP-1 Receptor Agonist by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 122: France Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: France Historic Review for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: France 15-Year Perspective for GLP-1 Receptor Agonist by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
    • TABLE 125: France Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: France Historic Review for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: France 15-Year Perspective for GLP-1 Receptor Agonist by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application and Obesity Application for the Years 2015, 2025 & 2030
  • GERMANY
    • GLP-1 Receptor Agonist Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 128: Germany Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Germany Historic Review for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Germany 15-Year Perspective for GLP-1 Receptor Agonist by Product - Percentage Breakdown of Value Sales for Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products for the Years 2015, 2025 & 2030
    • TABLE 131: Germany Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Germany Historic Review for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Germany 15-Year Perspective for GLP-1 Receptor Agonist by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 134: Germany Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Germany Historic Review for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Germany 15-Year Perspective for GLP-1 Receptor Agonist by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
    • TABLE 137: Germany Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Germany Historic Review for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Germany 15-Year Perspective for GLP-1 Receptor Agonist by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application and Obesity Application for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 140: Italy Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Italy Historic Review for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Italy 15-Year Perspective for GLP-1 Receptor Agonist by Product - Percentage Breakdown of Value Sales for Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products for the Years 2015, 2025 & 2030
    • TABLE 143: Italy Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Italy Historic Review for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Italy 15-Year Perspective for GLP-1 Receptor Agonist by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 146: Italy Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Italy Historic Review for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Italy 15-Year Perspective for GLP-1 Receptor Agonist by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
    • TABLE 149: Italy Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Italy Historic Review for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Italy 15-Year Perspective for GLP-1 Receptor Agonist by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application and Obesity Application for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • GLP-1 Receptor Agonist Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 152: UK Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: UK Historic Review for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: UK 15-Year Perspective for GLP-1 Receptor Agonist by Product - Percentage Breakdown of Value Sales for Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products for the Years 2015, 2025 & 2030
    • TABLE 155: UK Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: UK Historic Review for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: UK 15-Year Perspective for GLP-1 Receptor Agonist by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 158: UK Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: UK Historic Review for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: UK 15-Year Perspective for GLP-1 Receptor Agonist by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
    • TABLE 161: UK Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: UK Historic Review for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: UK 15-Year Perspective for GLP-1 Receptor Agonist by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application and Obesity Application for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 164: Spain Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Spain Historic Review for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Spain 15-Year Perspective for GLP-1 Receptor Agonist by Product - Percentage Breakdown of Value Sales for Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products for the Years 2015, 2025 & 2030
    • TABLE 167: Spain Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Spain Historic Review for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Spain 15-Year Perspective for GLP-1 Receptor Agonist by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 170: Spain Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Spain Historic Review for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Spain 15-Year Perspective for GLP-1 Receptor Agonist by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
    • TABLE 173: Spain Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Spain Historic Review for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Spain 15-Year Perspective for GLP-1 Receptor Agonist by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application and Obesity Application for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 176: Russia Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Russia Historic Review for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Russia 15-Year Perspective for GLP-1 Receptor Agonist by Product - Percentage Breakdown of Value Sales for Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products for the Years 2015, 2025 & 2030
    • TABLE 179: Russia Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Russia Historic Review for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Russia 15-Year Perspective for GLP-1 Receptor Agonist by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 182: Russia Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Russia Historic Review for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Russia 15-Year Perspective for GLP-1 Receptor Agonist by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
    • TABLE 185: Russia Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Russia Historic Review for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Russia 15-Year Perspective for GLP-1 Receptor Agonist by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application and Obesity Application for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 188: Rest of Europe Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Europe Historic Review for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Rest of Europe 15-Year Perspective for GLP-1 Receptor Agonist by Product - Percentage Breakdown of Value Sales for Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products for the Years 2015, 2025 & 2030
    • TABLE 191: Rest of Europe Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Europe Historic Review for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Rest of Europe 15-Year Perspective for GLP-1 Receptor Agonist by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 194: Rest of Europe Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Europe Historic Review for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Rest of Europe 15-Year Perspective for GLP-1 Receptor Agonist by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
    • TABLE 197: Rest of Europe Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Europe Historic Review for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Rest of Europe 15-Year Perspective for GLP-1 Receptor Agonist by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application and Obesity Application for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • GLP-1 Receptor Agonist Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 200: Asia-Pacific Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 201: Asia-Pacific Historic Review for GLP-1 Receptor Agonist by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Asia-Pacific 15-Year Perspective for GLP-1 Receptor Agonist by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 203: Asia-Pacific Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Asia-Pacific Historic Review for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Asia-Pacific 15-Year Perspective for GLP-1 Receptor Agonist by Product - Percentage Breakdown of Value Sales for Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products for the Years 2015, 2025 & 2030
    • TABLE 206: Asia-Pacific Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Asia-Pacific Historic Review for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Asia-Pacific 15-Year Perspective for GLP-1 Receptor Agonist by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 209: Asia-Pacific Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Asia-Pacific Historic Review for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Asia-Pacific 15-Year Perspective for GLP-1 Receptor Agonist by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
    • TABLE 212: Asia-Pacific Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Asia-Pacific Historic Review for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Asia-Pacific 15-Year Perspective for GLP-1 Receptor Agonist by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application and Obesity Application for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • GLP-1 Receptor Agonist Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 215: Australia Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Australia Historic Review for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Australia 15-Year Perspective for GLP-1 Receptor Agonist by Product - Percentage Breakdown of Value Sales for Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products for the Years 2015, 2025 & 2030
    • TABLE 218: Australia Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Australia Historic Review for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Australia 15-Year Perspective for GLP-1 Receptor Agonist by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 221: Australia Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Australia Historic Review for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Australia 15-Year Perspective for GLP-1 Receptor Agonist by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
    • TABLE 224: Australia Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Australia Historic Review for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Australia 15-Year Perspective for GLP-1 Receptor Agonist by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application and Obesity Application for the Years 2015, 2025 & 2030
  • INDIA
    • GLP-1 Receptor Agonist Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 227: India Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: India Historic Review for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: India 15-Year Perspective for GLP-1 Receptor Agonist by Product - Percentage Breakdown of Value Sales for Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products for the Years 2015, 2025 & 2030
    • TABLE 230: India Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: India Historic Review for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: India 15-Year Perspective for GLP-1 Receptor Agonist by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 233: India Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: India Historic Review for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: India 15-Year Perspective for GLP-1 Receptor Agonist by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
    • TABLE 236: India Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: India Historic Review for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: India 15-Year Perspective for GLP-1 Receptor Agonist by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application and Obesity Application for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 239: South Korea Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: South Korea Historic Review for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: South Korea 15-Year Perspective for GLP-1 Receptor Agonist by Product - Percentage Breakdown of Value Sales for Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products for the Years 2015, 2025 & 2030
    • TABLE 242: South Korea Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: South Korea Historic Review for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: South Korea 15-Year Perspective for GLP-1 Receptor Agonist by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 245: South Korea Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: South Korea Historic Review for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: South Korea 15-Year Perspective for GLP-1 Receptor Agonist by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
    • TABLE 248: South Korea Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: South Korea Historic Review for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: South Korea 15-Year Perspective for GLP-1 Receptor Agonist by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application and Obesity Application for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 251: Rest of Asia-Pacific Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Rest of Asia-Pacific Historic Review for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Rest of Asia-Pacific 15-Year Perspective for GLP-1 Receptor Agonist by Product - Percentage Breakdown of Value Sales for Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products for the Years 2015, 2025 & 2030
    • TABLE 254: Rest of Asia-Pacific Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Rest of Asia-Pacific Historic Review for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Rest of Asia-Pacific 15-Year Perspective for GLP-1 Receptor Agonist by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 257: Rest of Asia-Pacific Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Rest of Asia-Pacific Historic Review for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Rest of Asia-Pacific 15-Year Perspective for GLP-1 Receptor Agonist by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
    • TABLE 260: Rest of Asia-Pacific Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Rest of Asia-Pacific Historic Review for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Rest of Asia-Pacific 15-Year Perspective for GLP-1 Receptor Agonist by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application and Obesity Application for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • GLP-1 Receptor Agonist Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 263: Latin America Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 264: Latin America Historic Review for GLP-1 Receptor Agonist by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Latin America 15-Year Perspective for GLP-1 Receptor Agonist by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 266: Latin America Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Latin America Historic Review for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Latin America 15-Year Perspective for GLP-1 Receptor Agonist by Product - Percentage Breakdown of Value Sales for Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products for the Years 2015, 2025 & 2030
    • TABLE 269: Latin America Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Latin America Historic Review for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Latin America 15-Year Perspective for GLP-1 Receptor Agonist by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 272: Latin America Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Latin America Historic Review for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: Latin America 15-Year Perspective for GLP-1 Receptor Agonist by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
    • TABLE 275: Latin America Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Latin America Historic Review for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: Latin America 15-Year Perspective for GLP-1 Receptor Agonist by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application and Obesity Application for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 278: Argentina Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Argentina Historic Review for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: Argentina 15-Year Perspective for GLP-1 Receptor Agonist by Product - Percentage Breakdown of Value Sales for Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products for the Years 2015, 2025 & 2030
    • TABLE 281: Argentina Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Argentina Historic Review for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: Argentina 15-Year Perspective for GLP-1 Receptor Agonist by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 284: Argentina Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Argentina Historic Review for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: Argentina 15-Year Perspective for GLP-1 Receptor Agonist by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
    • TABLE 287: Argentina Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Argentina Historic Review for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: Argentina 15-Year Perspective for GLP-1 Receptor Agonist by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application and Obesity Application for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 290: Brazil Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Brazil Historic Review for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: Brazil 15-Year Perspective for GLP-1 Receptor Agonist by Product - Percentage Breakdown of Value Sales for Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products for the Years 2015, 2025 & 2030
    • TABLE 293: Brazil Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Brazil Historic Review for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: Brazil 15-Year Perspective for GLP-1 Receptor Agonist by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 296: Brazil Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Brazil Historic Review for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Brazil 15-Year Perspective for GLP-1 Receptor Agonist by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
    • TABLE 299: Brazil Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Brazil Historic Review for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: Brazil 15-Year Perspective for GLP-1 Receptor Agonist by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application and Obesity Application for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 302: Mexico Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Mexico Historic Review for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 304: Mexico 15-Year Perspective for GLP-1 Receptor Agonist by Product - Percentage Breakdown of Value Sales for Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products for the Years 2015, 2025 & 2030
    • TABLE 305: Mexico Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Mexico Historic Review for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 307: Mexico 15-Year Perspective for GLP-1 Receptor Agonist by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 308: Mexico Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Mexico Historic Review for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 310: Mexico 15-Year Perspective for GLP-1 Receptor Agonist by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
    • TABLE 311: Mexico Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Mexico Historic Review for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 313: Mexico 15-Year Perspective for GLP-1 Receptor Agonist by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application and Obesity Application for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 314: Rest of Latin America Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 315: Rest of Latin America Historic Review for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 316: Rest of Latin America 15-Year Perspective for GLP-1 Receptor Agonist by Product - Percentage Breakdown of Value Sales for Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products for the Years 2015, 2025 & 2030
    • TABLE 317: Rest of Latin America Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 318: Rest of Latin America Historic Review for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 319: Rest of Latin America 15-Year Perspective for GLP-1 Receptor Agonist by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 320: Rest of Latin America Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 321: Rest of Latin America Historic Review for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 322: Rest of Latin America 15-Year Perspective for GLP-1 Receptor Agonist by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
    • TABLE 323: Rest of Latin America Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 324: Rest of Latin America Historic Review for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 325: Rest of Latin America 15-Year Perspective for GLP-1 Receptor Agonist by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application and Obesity Application for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • GLP-1 Receptor Agonist Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 326: Middle East Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 327: Middle East Historic Review for GLP-1 Receptor Agonist by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 328: Middle East 15-Year Perspective for GLP-1 Receptor Agonist by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 329: Middle East Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 330: Middle East Historic Review for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 331: Middle East 15-Year Perspective for GLP-1 Receptor Agonist by Product - Percentage Breakdown of Value Sales for Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products for the Years 2015, 2025 & 2030
    • TABLE 332: Middle East Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 333: Middle East Historic Review for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 334: Middle East 15-Year Perspective for GLP-1 Receptor Agonist by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 335: Middle East Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 336: Middle East Historic Review for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 337: Middle East 15-Year Perspective for GLP-1 Receptor Agonist by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
    • TABLE 338: Middle East Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 339: Middle East Historic Review for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 340: Middle East 15-Year Perspective for GLP-1 Receptor Agonist by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application and Obesity Application for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 341: Iran Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 342: Iran Historic Review for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 343: Iran 15-Year Perspective for GLP-1 Receptor Agonist by Product - Percentage Breakdown of Value Sales for Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products for the Years 2015, 2025 & 2030
    • TABLE 344: Iran Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 345: Iran Historic Review for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 346: Iran 15-Year Perspective for GLP-1 Receptor Agonist by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 347: Iran Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 348: Iran Historic Review for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 349: Iran 15-Year Perspective for GLP-1 Receptor Agonist by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
    • TABLE 350: Iran Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 351: Iran Historic Review for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 352: Iran 15-Year Perspective for GLP-1 Receptor Agonist by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application and Obesity Application for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 353: Israel Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 354: Israel Historic Review for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 355: Israel 15-Year Perspective for GLP-1 Receptor Agonist by Product - Percentage Breakdown of Value Sales for Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products for the Years 2015, 2025 & 2030
    • TABLE 356: Israel Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 357: Israel Historic Review for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 358: Israel 15-Year Perspective for GLP-1 Receptor Agonist by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 359: Israel Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 360: Israel Historic Review for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 361: Israel 15-Year Perspective for GLP-1 Receptor Agonist by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
    • TABLE 362: Israel Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 363: Israel Historic Review for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 364: Israel 15-Year Perspective for GLP-1 Receptor Agonist by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application and Obesity Application for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 365: Saudi Arabia Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 366: Saudi Arabia Historic Review for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 367: Saudi Arabia 15-Year Perspective for GLP-1 Receptor Agonist by Product - Percentage Breakdown of Value Sales for Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products for the Years 2015, 2025 & 2030
    • TABLE 368: Saudi Arabia Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 369: Saudi Arabia Historic Review for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 370: Saudi Arabia 15-Year Perspective for GLP-1 Receptor Agonist by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 371: Saudi Arabia Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 372: Saudi Arabia Historic Review for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 373: Saudi Arabia 15-Year Perspective for GLP-1 Receptor Agonist by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
    • TABLE 374: Saudi Arabia Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 375: Saudi Arabia Historic Review for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 376: Saudi Arabia 15-Year Perspective for GLP-1 Receptor Agonist by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application and Obesity Application for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 377: UAE Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 378: UAE Historic Review for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 379: UAE 15-Year Perspective for GLP-1 Receptor Agonist by Product - Percentage Breakdown of Value Sales for Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products for the Years 2015, 2025 & 2030
    • TABLE 380: UAE Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 381: UAE Historic Review for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 382: UAE 15-Year Perspective for GLP-1 Receptor Agonist by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 383: UAE Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 384: UAE Historic Review for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 385: UAE 15-Year Perspective for GLP-1 Receptor Agonist by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
    • TABLE 386: UAE Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 387: UAE Historic Review for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 388: UAE 15-Year Perspective for GLP-1 Receptor Agonist by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application and Obesity Application for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 389: Rest of Middle East Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 390: Rest of Middle East Historic Review for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 391: Rest of Middle East 15-Year Perspective for GLP-1 Receptor Agonist by Product - Percentage Breakdown of Value Sales for Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products for the Years 2015, 2025 & 2030
    • TABLE 392: Rest of Middle East Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 393: Rest of Middle East Historic Review for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 394: Rest of Middle East 15-Year Perspective for GLP-1 Receptor Agonist by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 395: Rest of Middle East Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 396: Rest of Middle East Historic Review for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 397: Rest of Middle East 15-Year Perspective for GLP-1 Receptor Agonist by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
    • TABLE 398: Rest of Middle East Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 399: Rest of Middle East Historic Review for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 400: Rest of Middle East 15-Year Perspective for GLP-1 Receptor Agonist by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application and Obesity Application for the Years 2015, 2025 & 2030
  • AFRICA
    • GLP-1 Receptor Agonist Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 401: Africa Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 402: Africa Historic Review for GLP-1 Receptor Agonist by Product - Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 403: Africa 15-Year Perspective for GLP-1 Receptor Agonist by Product - Percentage Breakdown of Value Sales for Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and Other Products for the Years 2015, 2025 & 2030
    • TABLE 404: Africa Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 405: Africa Historic Review for GLP-1 Receptor Agonist by Route Of Administration - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 406: Africa 15-Year Perspective for GLP-1 Receptor Agonist by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 407: Africa Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 408: Africa Historic Review for GLP-1 Receptor Agonist by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 409: Africa 15-Year Perspective for GLP-1 Receptor Agonist by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
    • TABLE 410: Africa Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 411: Africa Historic Review for GLP-1 Receptor Agonist by Application - Type 2 Diabetes Mellitus Application and Obesity Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 412: Africa 15-Year Perspective for GLP-1 Receptor Agonist by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Mellitus Application and Obesity Application for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제